Mr. Hulse has over thirty five years experience building new businesses based on new technology, either in a deal-making or operating role, most recently in the area of biopharmaceuticals. He has led a wide range of assignments for Sage. While at The Sage Group, Mr. Hulse served as Chief Operating Officer of Hemispherx Biopharma, a public biotechnology company commercializing unique double-stranded RNA technology.

Before joining The Sage Group, he built the business development activity at Enzon, Inc., an emerging biopharmaceutical company exploiting proprietary drug delivery technologies, as a consultant and later as Vice President of Business Development. Mr. Hulse completed over 30 deals in his last three years at Enzon.

Prior to joining Enzon, Mr. Hulse specialized in high technology start-ups, serving as Founder and Chief Executive Officer for growth companies such as Sunstone, Inc., Envirometrics, Polycyclose Technologies and i-STAT Corporation, currently the leader in point-of -care diagnostics with a market capitalization in excess of $200 million.

Previously, he has been a Vice President of Engelhard Industries, responsible for new ventures, diversification, and strategic planning, and a Vice President and General Manager with Halcon International, where he managed a $20 million division, with full P&L responsibility.

As Director of Business Planning at Halcon, Mr. Hulse led the team establishing the largest chemical joint venture in Japan as well as acted as principal business negotiator in borrowing over $250 million in a project financing for a major chemical complex in Texas.

He is a Phi Beta Kappa graduate of Princeton University in Chemistry and holds Masters degrees in Chemical Engineering and Industrial Management from MIT.

Mr. Hulse is active in the Licensing Executives Society and the Biotechnology Council of New Jersey. He serves on the Board of SDTX Technologies, Inc., Captiva Technologies, Inc., and Carnagie Venture Resources, Inc.